查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835595

多發性骨髓瘤藥物市場按藥物類別、治療線、治療方法、給藥途徑、患者年齡、性別和配銷通路分類 - 全球預測 2025-2032

Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多發性骨髓瘤治療市場將成長至 463.2 億美元，複合年成長率為 8.27%。

主要市場統計數據
基準年2024年 245.1億美元
預計2025年 265.2億美元
預測年份：2032年 463.2億美元
複合年成長率（%） 8.27%

一份全面的概述文件，定義了治療層級、臨床決策節點和治療實施變量，這些變量影響了多發性骨髓瘤的管理

多發性骨髓瘤已從骨髓惡性腫瘤演變為一個複雜且需要長期管理的疾病領域，其特點是快速的治療創新和細緻入微的患者治療路徑。目前，該領域涵蓋了標靶小分子藥物、免疫調節化合物、生技藥品和精準定向平台，每種藥物都在改變臨床實踐模式和付款人互動。在此背景下，相關人員需要一份簡明的、基於證據的介紹，闡明治療類別、其實際給藥路徑以及影響其應用的商業性槓桿。

本執行導言透過闡明目前的治療分類和常見的臨床決策標準奠定了基礎。關鍵藥物類別包括組蛋白去乙醯化酶抑制劑，例如Panobinostat；免疫調節劑，例如Lenalidomide胺、泊馬度Pomalidomide和Thalidomide；單株抗體，例如Daratumumab尤單抗、Elotuzumab和伊沙妥昔單抗；以及蛋白酶體抑制劑，例如Bortezomib、Carfilzomib和Ixazomib。除了這些類別之外，治療方法選擇還受到從一線到三線及以上治療方案的考慮，以及從單一療法到包括兩種、三種和四種藥物聯合治療在內的多種方案配置的影響。

最後，引言部分重點介紹了影響實際使用情況的實際變量，例如給藥途徑（靜脈注射、口服、皮下注射等）、患者人口統計數據（60歲以上 vs 60歲以下）、性別差異的護理管道以及配銷通路的差異（醫院、線上藥店、零售藥店等）。透過闡明這些基本要素，本節將幫助管理人員和臨床醫生準確、結合情境解讀後續章節。

深入研究從根本上改變多發性骨髓瘤治療方法和商業化動態的治療、交付和監管變化

多發性骨髓瘤的治療模式正在經歷一場變革，其驅動力在於機制多樣化、最佳化的聯合治療以及以患者為中心的醫療服務模式。蛋白酶體抑制劑和免疫調節劑通常與單株抗體聯用，以增強療效的深度和持久性。同時，生技藥品和免疫效應技術的日益成熟，正在重新調整研發重點，促使發起人尋求更早的適應症和合併用藥策略，從而重新定義治療標準。

科技變革也在重塑醫療保健服務。口服和皮下生技藥品縮短了診療時間，並支持門診病人管理。如今，治療方法創新往往強調在一線治療中採用三聯或四聯療法（如果患者耐受），同時優先考慮序貫和聯合治療的靈活性，以應對二線及以上治療的抗藥性。這種轉變伴隨著監管和真實世界證據預期的不斷變化，要求研發人員不僅要證明療效，還要證明在生活品質、疾病進展預防和資源利用方面的相對效益。

因此，商業模式也在不斷調整。製造商和醫療保健提供者必須根據不同治療線的差異化臨床特徵調整產品定位，根據患者年齡層和性別客製化通訊，並設計涵蓋醫院藥房、零售店以及日益成長的線上管道的分銷策略。這將導致市場格局更加快速變化，細分化程度更高，而策略敏捷性和多學科證據產生能力將成為競爭優勢。

對 2025 年關稅政策變化如何重塑多發性骨髓瘤治療的供應鏈、製造決策、價格談判和獲取管道的策略評估。

2025年美國新關稅的實施將為全球醫藥供應鏈帶來新的複雜性，影響採購、製造和成本管理。關稅導致的成本上漲將影響原料藥藥物成分的採購、中間體成分以及某些進口生技藥品，迫使製造商重新評估其供應商組合，並透過盡可能轉移或本地化生產來減輕影響。這些策略調整將影響短期產業計畫和長期產能資本投資。

同時，關稅引發的波動將影響定價以及與付款人和綜合配送網路的合約談判。製藥公司將面臨壓力，需要消化增加的成本、協商續約報銷協議，並實施有針對性的患者支持策略以維持患者可及性。對於依賴複雜低溫運輸物流和專業配送的治療方法，例如單株抗體的靜脈注射，關稅和不斷上漲的物流成本將增加對綜合供應鏈韌性的需求。

此外，關稅促使人們重新評估不同治療層級和給藥偏好的商業策略。減輕臨床負擔的口服製劑可以抵禦分銷成本的波動，而醫院的靜脈注射療法可能面臨更嚴格的營運成本審查。對於決策者而言，關稅措施的累積影響需要跨部門的應對，涵蓋採購、監管規劃、市場進入和價值溝通，以保障病患用藥管道並維持醫療服務的連續性。

實證細分洞察揭示了藥物類別、治療線、方案架構、給藥途徑、人口統計和分佈如何影響臨床和商業性選擇

這項研究的見解揭示了臨床、人口統計和分佈變數如何相互影響，從而影響治療方法選擇和商業性優先順序。依藥物類別分析，來Lenalidomide、Pomalidomide和Thalidomide等免疫調節劑仍是多種治療方案的基石，通常與Bortezomib、Carfilzomib和Ixazomib等蛋白酶體抑制劑聯合使用，構成骨幹方案。Daratumumab、Elotuzumab和伊沙妥昔單抗等單株抗體擴大被用於聯合治療以增強療效，而組蛋白去乙醯化酶抑制劑（如Panobinostat）在某些難治性治療中也發揮作用。

治療線從一線線到三線及以上細分，第一線治療優先考慮耐受性和長期疾病控制，而後期治療則強調挽救療效和治療順序靈活性。單一療法和聯合治療治療方法之間的區別至關重要。聯合治療，無論是兩種、三種或四種藥物，都能提高緩解率，但也會增加毒性管理、支持性治療和報銷考量。依給藥途徑細分可以明確以病人為中心的權衡。靜脈注射和皮下生技藥品需要臨床資源，而口服藥物支持門診管理，並可能提高依從性。

患者年齡層（60歲以上與60歲以下）和性別的差異會影響耐受性評估、合併症管理和移植合格，進一步最佳化治療決策。最後，分銷管道（醫院、線上和零售藥局）的細分影響著藥物的可及性和病患體驗，每個管道都有不同的物流、報銷和病患支援要求。整合這些細分市場，可以製定量身定做的臨床開發和商業策略，使產品特性與現實世界的治療管道保持一致。

區域重點關注美洲、歐洲、中東和非洲地區以及亞太地區的治療模式、監管流程、報銷環境和人口結構差異

區域動態持續對多發性骨髓瘤治療策略產生決定性影響，美洲、中東和非洲以及亞太地區各自展現出不同的臨床實踐、報銷框架和患者人口統計。在美洲，重點是快速引入新型藥物和組合方案，這得益於先進的臨床實驗室網路和鼓勵明確價值差異化並根據實際療效進行獎勵的支付方環境。在該地區，關於藥物可及性的討論通常圍繞著展示總體生存獲益、改善無惡化生存期以及健康經濟價值提案。

歐洲、中東和非洲地區醫療保健資金籌措模式和監管要求各異，因此需要製定針對特定地區的實證規劃和定價策略。集中式監管管道與國家級報銷決策並存，因此制定本地衛生技術評估文件和真實世界證據對於確保醫療資源的可及性至關重要。在該地區的許多國家，治療提供模式強調醫院管理，這影響了人們對皮下注射劑型和通訊協定的偏好，從而簡化了輸液中心的診療流程。

亞太市場受人口趨勢和醫療現代化舉措的驅動，包括加速臨床研究以及對口腔和門診病人友善治療的需求不斷成長。供應鏈和關稅政策在亞太部分地區也發揮關鍵作用，迫使製造商考慮區域製造夥伴關係和獨特的分銷模式。在整個地區，人口結構的變化，例如年齡分佈和性別相關流行病學，將進一步影響產品定位和上市管道。

對競爭定位進行簡明的策略回顧，其中現有特許經營權、新進業者和合作策略定義了臨床差異化和商業性優勢

多發性骨髓瘤領域的競爭動態將由既有的腫瘤學領導企業，也由敏捷的專業生物技術公司共同決定，這些公司將透過創新機制、聯合用藥策略和實證項目推動治療差異化發展。以蛋白酶體抑制劑和免疫調節劑為中心的現有產品系列將繼續在臨床管道中發揮核心作用，而單株抗體業務則已擴展其適應症和服務模式，以支持臨床和皮下給藥。

新參與企業正透過雙特異性抗體、細胞療法和下一代標靶藥物加速創新，迫使大型機構投資於聯合測試和生命週期管理策略。策略活動包括透過領先測試擴大適應症，改進製劑以增強門診病人給藥，以及開發伴隨診斷和生物標記策略以最佳化患者選擇。隨著企業尋求互補資產以建立穩健的治療方案並擴大地域覆蓋範圍，夥伴關係和許可安排變得十分常見。

從商業性角度來看，企業正透過患者援助解決方案、數位化依從性計劃以及將臨床結果與成本和生活品質指標相結合的綜合價值檔案來實現差異化。臨床證據、生產規模和付款人參與度的相互作用將決定競爭定位，而成功的企業將是那些將科學差異化與卓越營運以及對醫療保健系統和患者可證明的價值相結合的企業。

為商業性和臨床領導者提供可操作的協作策略步驟，以確保多發性骨髓瘤的可近性、最佳化治療方案並增強供應彈性

致力於在多發性骨髓瘤領域奠定堅實基礎的產業領導者應採取協調一致、切實可行的干涉措施，以解決臨床鑑別診斷、藥物可近性和營運韌性等問題。這包括頭對頭試驗和反映常規給藥途徑和患者群體的實用觀察性研究。其次，他們應制定最佳化方案互換性的投資組合策略，使其能夠將自身資產有效配置於雙聯、三聯和四聯治療框架，同時兼顧耐受性和支持性治療需求。

同時，投資於能夠反映不斷變化的醫療環境的分銷和患者援助模式。盡可能加強門診和家庭管理能力，並與醫院藥房相關人員和線上零售管道協同努力。多元化供應鏈和本地生產應急計劃，以降低關稅波動和物流中斷帶來的風險。從商業性角度來看，透過將臨床終點與經濟效益掛鉤，完善與付款人的價值溝通，並制定有針對性的患者援助計劃，以維持口服和注射藥物的依從性。

最後，研發、市場准入和商業團隊將跨職能合作，加速適應症擴大策略，並確保證據產生符合報銷要求。透過實施這些協調一致的行動，產業領導者能夠在快速發展的多發性骨髓瘤領域改善藥物可及性、維持藥物使用量並維持長期治療相關性。

一種透明的多方法研究途徑，結合主要專家訪談、系統文獻綜合和交叉檢驗的分析技術，以產生可靠的研究結果

本報告的調查方法嚴格整合了已發表的科學文獻、監管備案文件、臨床試驗註冊中心以及與臨床醫生、付款方和商業行業領袖的相關人員訪談。主要研究部分包括與多個執業機構的關鍵意見領袖和主治醫生進行結構化訪談，以檢驗臨床應用模式，並了解現實世界中的耐受性和用藥偏好。次要研究部分包括對同行評審研究、監管文件和指南的系統性綜述，以確定治療機制、適應症和安全性。

採用交叉驗證技術確保實驗室結果與實際使用情況的一致性，並採用資料三角測量法協調不同資訊來源的發現。透過提取目標資料集並進行專家驗證，實現了細分領域的覆蓋，包括藥物類別（組蛋白去乙醯化酶抑制劑、免疫調節劑、單株抗體、蛋白酶體抑制劑）、治療線差異、方案結構、給藥途徑、患者年齡和性別組以及分銷管道。區域分析資料來自監管文件以及對美洲、中東和檢驗以及亞太地區當地市場專家的訪談。

分析方法包括對訪談資料進行定性主題編碼、不同治療層級的效益風險比較評估，以及基於情境的影響模型，以評估關稅效應和供應鏈調整等策略影響。調查方法的來源和限制保持透明，以提高可重複性並指導研究結果的適當解讀。

整合臨床創新、營運現實和政策動態的結論性綜合報告，指導多發性骨髓瘤的策略決策

本執行摘要強調，多發性骨髓瘤是一個快速發展的治療領域，臨床創新、變革性交付模式和政策轉變正在交織在一起，重新定義患者照護和商業策略。先進生技藥品、最佳化組合方案和病患偏好給藥途徑的融合，需要採取整體方法進行證據產生、供應鏈設計和上市規劃。將臨床差異化與現實運作能力相結合的相關人員將最有能力將科學進步轉化為持久的患者效益。

此外，諸如關稅變化和區域監管差異等外部因素需要採取積極主動的跨職能應對措施，以維持藥物的可及性和可負擔性。整合細分洞察——從藥物類別和治療線到方案配置、給藥途徑、年齡/性別和分銷管道——能夠實現更精準的產品定位和量身定做的上市策略。最終，能否展示有意義的臨床效益、管理物流複雜性以及向付款人和提供者傳達價值，將決定哪些治療方法能夠獲得持久的採用，哪些療法面臨可及性治療方法。

因此，決策者應採取協作方式，在積極的證據生成和現實的商業化計劃之間取得平衡，以確保治療方法創新能夠顯著改善患者的治療效果並為醫療保健系統帶來價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • BCMA標靶CAR-T細胞療法在復發/難治性多發性骨髓瘤患者的臨床應用日益增多
  • 擴大口服蛋白酶體抑制劑聯合治療改善多發性骨髓瘤的第一線治療效果
  • 下一代 cereblon E3 連接酶調變器的出現提高了多發性骨髓瘤的緩解率
  • 實施個人化微量殘存疾病監測以指導多發性骨髓瘤治療調整
  • 開發 BCMA 以外的多種骨髓瘤表面抗原的雙特異性抗體平台
  • 擴大抗體-藥物偶聯物產品線，開發新型有效載荷，用於靶向多發性骨髓瘤治療
  • 利用真實世界證據支持多發性骨髓瘤治療藥物的監管核准和市場進入
  • 整合先進的影像和液態生物檢體生物標記物，用於多發性骨髓瘤復發的早期檢測

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

8. 多發性骨髓瘤藥物市場（依藥物類別）

  • 組蛋白去乙醯化酶抑制劑
    • Panobinostat
  • 免疫調節藥物
    • Lenalidomide
    • Pomalidomide
    • Thalidomide
  • 單株抗體
    • Daratumumab
    • Elotuzumab
    • 伊沙妥昔單抗
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • Ixazomib

9. 多發性骨髓瘤藥物市場（依治療線）

  • 一線
  • 第二行
  • 三線以上

第 10 章：多發性骨髓瘤藥物市場（依治療方法）

  • 聯合治療
    • 雙聯療法
    • 四聯療法
    • 三聯療法
  • 單一療法

第 11 章：多發性骨髓瘤藥物市場（依給藥途徑）

  • 靜脈
  • 口服
  • 皮下

第 12 章：多發性骨髓瘤藥物市場（依病患年齡）

  • 60歲或以上
  • 60歲以下

13. 多發性骨髓瘤藥物市場（依性別）

  • 女士
  • 男性

14. 多發性骨髓瘤藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

15. 多發性骨髓瘤藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 16 章：多發性骨髓瘤藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 多發性骨髓瘤藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bristol-Myers Squibb Company
    • Janssen BIoTech, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Novartis International AG
    • AbbVie Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Karyopharm Therapeutics Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3A894

The Multiple Myeloma Drug Market is projected to grow by USD 46.32 billion at a CAGR of 8.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.51 billion
Estimated Year [2025] USD 26.52 billion
Forecast Year [2032] USD 46.32 billion
CAGR (%) 8.27%

A comprehensive orienting overview that defines therapeutic classes, clinical decision nodes, and care delivery variables shaping multiple myeloma management

Multiple myeloma has evolved from a terminal hematologic malignancy to a complex, chronically managed disease area characterized by rapid therapeutic innovation and nuanced patient pathways. The landscape now interweaves targeted small molecules, immune-modulating compounds, biologics, and precision-directed platforms, each altering clinical practice patterns and payer conversations. Against this backdrop, stakeholders require a succinct, evidence-driven introduction that clarifies therapeutic categories, real-world administration pathways, and the commercial levers shaping adoption.

This executive introduction sets the stage by articulating the current therapeutic taxonomy and common clinical decision nodes. Drug classes of central relevance include histone deacetylase inhibitors exemplified by panobinostat, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide, monoclonal antibodies including daratumumab, elotuzumab, and isatuximab, and proteasome inhibitors represented by bortezomib, carfilzomib, and ixazomib. Alongside these classes, treatment selection is influenced by line of therapy considerations spanning first line through third and beyond, and by regimen architecture that ranges from monotherapy to combination approaches including doublet, triplet, and quadruplet regimens.

Finally, the introduction underscores practical variables that shape real-world utilization: routes of administration including intravenous, oral, and subcutaneous delivery; patient demographic factors such as age cohorts sixty and above versus under sixty; gender-specific care pathways; and distribution channel distinctions across hospital, online, and retail pharmacy settings. By clarifying these foundational elements, this section equips executives and clinicians to interpret subsequent sections with precision and context.

An in-depth exploration of the therapeutic, delivery, and regulatory shifts fundamentally altering multiple myeloma treatment approaches and commercialization dynamics

Multiple myeloma treatment paradigms are undergoing transformative shifts driven by mechanistic diversification, combination optimization, and patient-centric delivery models. Over recent years, the field has moved beyond sequential monotherapy toward rationally designed combinations that leverage complementary mechanisms of action; proteasome inhibitors and immunomodulatory agents are commonly paired with monoclonal antibodies to enhance depth and durability of response. Concurrently, the maturation of biologics and immune effector technologies has reoriented R&D priorities, prompting sponsors to pursue earlier-line indications and combination strategies that redefine standard-of-care benchmarks.

Technological changes are also reshaping care delivery. Oral formulations and subcutaneous biologic options reduce clinic time and support outpatient management, which in turn influences payer negotiations and patient adherence dynamics. Treatment regimen innovation now frequently emphasizes triplet and quadruplet approaches in frontline settings where tolerability permits, while second-line and later settings prioritize sequencing and combination flexibility to manage resistance. These shifts are accompanied by evolving regulatory pathways and real-world evidence expectations, requiring developers to demonstrate not only efficacy but also comparative benefits in quality of life, progression control, and resource utilization.

As a result, commercial models are adapting: manufacturers and providers must align product positioning with differentiated clinical profiles across lines of therapy, tailor messaging for distinct patient age cohorts and genders, and design distribution strategies that incorporate hospital pharmacies, retail outlets, and increasingly important online channels. The net effect is a faster-moving, more fragmented landscape where strategic agility and multidisciplinary evidence generation confer competitive advantage.

A strategic assessment of how tariff policy shifts in 2025 are reshaping supply chains, manufacturing decisions, pricing negotiations, and access pathways in multiple myeloma care

The implementation of new United States tariff measures in 2025 has introduced an additional layer of complexity to global pharmaceutical supply chains, with implications for sourcing, manufacturing, and cost management. Tariff-driven cost inflation affects active pharmaceutical ingredient procurement, intermediate components, and certain imported biologic materials, prompting manufacturers to reassess supplier portfolios and, where feasible, repatriate or regionalize production to mitigate exposure. These strategic adjustments shape both short-term operational planning and longer-term capital investments in manufacturing capacity.

In parallel, tariff-induced changes influence pricing and contracting discussions with payers and integrated delivery networks. Pharmaceutical companies face pressure to absorb incremental costs, negotiate updated reimbursement terms, or implement targeted patient assistance strategies to preserve access. For therapies that rely on complex cold-chain logistics and specialized distribution-such as monoclonal antibodies administered intravenously or subcutaneously-the combination of tariffs and logistics cost increases intensifies the need for integrated supply chain resilience.

Moreover, tariffs catalyze a reevaluation of commercial strategy across therapeutic classes and route-of-administration preferences. Oral agents that reduce clinic burden can offer resilience against distribution cost volatility, while hospital-centric intravenous therapies may face more pronounced operational cost scrutiny. For decision-makers, the cumulative impact of tariff policy requires a cross-functional response that spans procurement, regulatory planning, market access, and value communication to sustain patient access and preserve therapeutic continuity.

Empirical segmentation insights revealing how drug class, therapy line, regimen architecture, administration route, demographics, and distribution converge to shape clinical and commercial choices

Segmentation-driven insight reveals how clinical, demographic, and distribution variables intersect to influence therapeutic selection and commercial priorities. When analyzing drug classes, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide remain foundational across many lines of therapy and are frequently paired with proteasome inhibitors like bortezomib, carfilzomib, and ixazomib to create backbone regimens. Monoclonal antibodies, including daratumumab, elotuzumab, and isatuximab, are increasingly used in combination strategies to deepen responses, while histone deacetylase inhibitors exemplified by panobinostat occupy a role in selected refractory settings.

Line of therapy segmentation-spanning first line through third and beyond-drives regimen architecture, with frontline treatments prioritizing tolerability and long-term disease control, and later lines emphasizing salvage efficacy and sequencing flexibility. Treatment regimen distinctions between monotherapy and combination therapy are critical: combination approaches, whether doublet, triplet, or quadruplet, are driving improved response rates but also elevate considerations around toxicity management, supportive care, and reimbursement. Route of administration segmentation underscores patient-centric trade-offs; intravenous and subcutaneous biologics demand clinic resources, whereas oral agents support outpatient management and potentially higher adherence.

Patient age cohorts-sixty and above versus under sixty-and gender differences further refine therapeutic decisions, influencing tolerability assessments, comorbidity management, and transplant eligibility considerations. Finally, distribution channel segmentation across hospital, online, and retail pharmacies shapes access and patient experience, with each channel imposing distinct logistical, reimbursement, and patient support requirements. Integrating these segmentation lenses enables tailored clinical development and commercial strategies that align product attributes with real-world care pathways.

A regionally focused analysis of how treatment patterns, regulatory processes, reimbursement environments, and demographic trends vary across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a decisive influence on multiple myeloma strategy, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct clinical practices, reimbursement frameworks, and patient demographics. In the Americas, practice patterns emphasize rapid adoption of novel agents and combination regimens, buoyed by advanced clinical trial networks and a payer environment that increasingly rewards clear value differentiation and real-world outcomes. Access conversations in this region are often centered on demonstrating overall survival benefit, progression-free survival improvements, and health economic value propositions.

In Europe, the Middle East, and Africa, heterogeneity in healthcare funding models and regulatory requirements necessitates region-specific evidence plans and pricing strategies. Centralized regulatory pathways coexist with country-level reimbursement decisions, making local health technology assessment dossiers and real-world evidence generation essential to secure access. In many countries across this region, treatment delivery models emphasize hospital-based administration, which influences preferences for subcutaneous formulations and protocols that streamline infusion center throughput.

Asia-Pacific markets demonstrate accelerating clinical research activity and rising demand for oral and outpatient-friendly therapeutics driven by demographic trends and healthcare modernization initiatives. Supply chain considerations and tariff policies also play a heightened role in some Asia-Pacific jurisdictions, prompting manufacturers to consider regional manufacturing partnerships and tailored distribution models. Across all regions, demographic variations such as age distribution and gender-related epidemiology further inform product positioning and market access pathways.

A concise strategic review of competitive positioning where incumbent franchises, novel entrants, and partnership strategies define clinical differentiation and commercial advantage

Competitive dynamics in multiple myeloma are defined by both established oncology leaders and agile specialty biotechs that drive therapeutic differentiation through novel mechanisms, combination strategies, and evidence-generation programs. Incumbent product portfolios anchored by proteasome inhibitors and immunomodulatory agents continue to play a central role in clinical pathways, while monoclonal antibody franchises have expanded indications and service models to support clinic-based and subcutaneous administration.

Emerging entrants are accelerating innovation through bispecific antibodies, cellular therapies, and next-generation targeted agents, compelling larger organizations to invest in combination trials and lifecycle management tactics. Strategic activity includes label expansion through earlier-line studies, formulation improvements that enhance outpatient delivery, and the development of companion diagnostics or biomarker strategies that refine patient selection. Partnerships and licensing arrangements are prevalent as companies seek complementary assets to build robust regimen offerings and to broaden geographic reach.

From a commercial perspective, companies are differentiating through patient support solutions, digital adherence programs, and integrated value dossiers that align clinical outcomes with cost and quality-of-life metrics. The interplay between clinical evidence, manufacturing scale, and payer engagement determines competitive positioning, and successful players will be those that align scientific differentiation with operational excellence and demonstrable value to health systems and patients.

Actionable and coordinated strategic moves for commercial and clinical leaders to secure access, optimize regimens, and strengthen supply resilience in multiple myeloma

Industry leaders seeking to strengthen their foothold in multiple myeloma should pursue a set of coordinated, actionable interventions that address clinical differentiation, access, and operational resilience. First, prioritize the generation of comparative and real-world evidence that demonstrates clinical benefit beyond existing standards of care across relevant lines of therapy; this includes head-to-head studies and pragmatic observational research that reflect routine administration routes and patient demographics. Second, design portfolio strategies that optimize regimen compatibility, enabling your assets to be convincingly positioned in doublet, triplet, or quadruplet frameworks while managing tolerability and supportive care needs.

Simultaneously, invest in distribution and patient support models that reflect shifting care settings: enhance capabilities for outpatient and home-based administration where feasible, and tailor engagement for hospital pharmacy stakeholders and online retail channels. Supply chain diversification and regional manufacturing contingency planning will mitigate exposure to tariff volatility and logistics disruption. From a commercial standpoint, refine value communication to payers by linking clinical endpoints to economic outcomes, and develop targeted patient assistance programs that maintain adherence across oral and injectable modalities.

Finally, embed cross-functional collaboration among R&D, market access, and commercial teams to accelerate label expansion strategies and to ensure evidence generation aligns with reimbursement requirements. By executing these linked actions, industry leaders can enhance access, sustain uptake, and preserve long-term therapeutic relevance in a rapidly evolving multiple myeloma landscape.

A transparent and multi-method research approach combining primary expert interviews, systematic literature synthesis, and cross-validated analytical techniques to ensure robust insights

The research methodology for this report combines a rigorous synthesis of public scientific literature, regulatory filings, clinical trial registries, and stakeholder interviews with clinicians, payers, and commercial leaders. Primary research components include structured interviews with key opinion leaders and treating physicians across multiple practice settings to validate clinical adoption patterns and to capture real-world tolerability and administration preferences. Secondary research involves systematic review of peer-reviewed studies, regulatory documentation, and guideline statements to map therapeutic mechanisms, label indications, and safety profiles.

Data triangulation was employed to reconcile insights from disparate sources, using cross-validation techniques to ensure consistency between clinical trial outcomes and observed real-world usage. Coverage of segmentation lenses-drug class including histone deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors; line of therapy distinctions; regimen architecture; route of administration; patient age and gender cohorts; and distribution channels-was achieved through targeted dataset extraction and expert validation. Regional analyses were informed by jurisdictional regulatory materials and interviews with local market experts in the Americas, Europe Middle East & Africa, and Asia-Pacific.

Analytical methods included qualitative thematic coding of interview data, comparative benefit-risk assessments across therapeutic classes, and scenario-based impact modeling to evaluate strategic implications such as tariff effects and supply chain adaptations. Throughout, transparency in source attribution and methodological limitations was maintained to support reproducibility and to guide appropriate interpretation of findings.

A concluding synthesis that integrates clinical innovation, operational realities, and policy dynamics to guide strategic decision-making in multiple myeloma

This executive synthesis underscores that multiple myeloma is a rapidly evolving therapeutic arena where clinical innovation, delivery model transformation, and policy shifts intersect to redefine patient care and commercial strategy. The convergence of advanced biologics, optimized combination regimens, and patient-preferred administration routes necessitates a holistic approach to evidence generation, supply chain design, and market access planning. Stakeholders who align clinical differentiation with pragmatic operational capabilities will be best positioned to translate scientific advances into sustained patient impact.

Moreover, external forces such as tariff changes and regional regulatory heterogeneity require proactive, cross-functional responses to preserve access and affordability. Integrating segmentation insights-from drug class and line of therapy through regimen composition, administration route, age and gender demographics, and distribution channels-enables more precise product positioning and tailored launch strategies. Ultimately, the capacity to demonstrate meaningful clinical benefit, manage logistical complexity, and communicate value to payers and providers will determine which therapies achieve durable uptake and which face access constraints.

Decision-makers should therefore take a coordinated approach that balances aggressive evidence generation with pragmatic commercialization planning, ensuring that therapeutic innovation translates into measurable improvements in patient outcomes and health system value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing clinical adoption of BCMA-directed CAR T-cell therapies in relapsed refractory multiple myeloma patients
  • 5.2. Expansion of oral proteasome inhibitor combination regimens improving frontline multiple myeloma treatment outcomes
  • 5.3. Emergence of next-generation cereblon E3 ligase modulators enhancing response rates in multiple myeloma
  • 5.4. Implementation of personalized minimal residual disease monitoring to guide therapy adjustments in multiple myeloma
  • 5.5. Development of bispecific antibody platforms targeting multiple myeloma surface antigens beyond BCMA
  • 5.6. Growing pipeline of antibody-drug conjugates combining novel payloads for targeted multiple myeloma therapy
  • 5.7. Use of real-world evidence to support regulatory approvals and market access for multiple myeloma therapies
  • 5.8. Integration of advanced imaging and liquid biopsy biomarkers for early detection of multiple myeloma relapse

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Drug Market, by Drug Class

  • 8.1. Histone Deacetylase Inhibitors
    • 8.1.1. Panobinostat
  • 8.2. Immunomodulatory Agents
    • 8.2.1. Lenalidomide
    • 8.2.2. Pomalidomide
    • 8.2.3. Thalidomide
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Daratumumab
    • 8.3.2. Elotuzumab
    • 8.3.3. Isatuximab
  • 8.4. Proteasome Inhibitors
    • 8.4.1. Bortezomib
    • 8.4.2. Carfilzomib
    • 8.4.3. Ixazomib

9. Multiple Myeloma Drug Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third And Beyond

10. Multiple Myeloma Drug Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. Doublet Regimen
    • 10.1.2. Quadruplet Regimen
    • 10.1.3. Triplet Regimen
  • 10.2. Monotherapy

11. Multiple Myeloma Drug Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Multiple Myeloma Drug Market, by Patient Age

  • 12.1. Sixty And Above
  • 12.2. Under Sixty

13. Multiple Myeloma Drug Market, by Gender

  • 13.1. Female
  • 13.2. Male

14. Multiple Myeloma Drug Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Multiple Myeloma Drug Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Multiple Myeloma Drug Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Multiple Myeloma Drug Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Bristol-Myers Squibb Company
    • 18.3.2. Janssen Biotech, Inc.
    • 18.3.3. Takeda Pharmaceutical Company Limited
    • 18.3.4. Amgen Inc.
    • 18.3.5. Novartis International AG
    • 18.3.6. AbbVie Inc.
    • 18.3.7. Sanofi S.A.
    • 18.3.8. GlaxoSmithKline plc
    • 18.3.9. Karyopharm Therapeutics Inc.
    • 18.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS